A lthough tissue microarrays (TMA) have been widely used in the cancer research field for high-throughput gene expression analysis and validation of tumor markers on tissue, [1] [2] [3] [4] [5] [6] [7] [8] cytology microarray (CMA) has not been tested in cytology samples for such a purpose. In particular, the use of CMA for the purpose of marker validation or other research has not been reported. There is 1 recent report using cytology material to construct microarray with success but no marker testing was performed in that study. 9 Cytology material is usually presented in the form of small cellular aggregates rather than the large tissue fragments seen in surgical pathology material. Whether the small cell clusters in cores of CMA will be representative of the standard section is not known. The objectives of this study are to first validate the utility of CMA in its representation of the original cell blocks in cell numbers and composition; and then to confirm that immunostains on CMA can recapitulate the original section with several antibodies frequently used in differential diagnosis of some common tumors.
MATERIALS AND METHODS
The authors constructed a microarray using standard cell blocks obtained from malignant effusions. The original tumors were known and the subsequent effusions were diagnosed by evaluation of morphology and often supported with immunocytochemical stain profile and clinical outcomes. Fresh effusions were centrifuged and sediments were used to make cell blocks by plasma-thrombin method. Briefly, after decanting supernatant, several drops of plasma and thrombin were added to the sediments to mix by gentle vortex and the mixture was then allowed to clot, followed by fixation with 10% buffered formalin solution for at least 1 hour (up to 10 hours) before being processed for embedding in paraffin block. A total of 23 malignant effusions of primary tumor of breast, lung, ovary, and gastrointestinal (GI) tract (including esophageal and pancreatic carcinoma) were used to construct a CMA so that 3 cores, each 0.6 mm in diameter, were taken from each of the original effusion cell blocks. Three cores were taken (Table 1) , staining cytoplasm (cytokeratin [CK] AE1/AE3, epithelial membrane antigen [EMA]), and nuclei (Ki-67) were applied to all of the original cell block sections and CMA according to established protocol and conditions. Selected antibodies that are useful in differential diagnosis of each primary cancer were also included: estrogen receptor (ER), progesterone receptor (PR), CK7, CK20, for breast cancer; thyroid transcription factor-1 (TTF-1), CK7, CK20, for lung cancer; CK20, CK7 for GI tract cancer; and WT-1 for ovarian cancer (Table 1) . Stain pattern and percentages of positively immunostained tumor cells on original cell block slides and on CMA were recorded for comparison. Cytoplasmic stain by AE1/AE3, CK7, and CK20 were considered positive patterns, whereas cytoplasmic and membranous stains for EMA and nuclear stain for Ki-67, ER, PR, TTF-1, and WT-1 were considered positive patterns. Stain intensity was recorded as negative (2) or positive (weak, 11; moderate, 12; and strong, 13), and the percentage of tumor cells that were positive were also recorded.
RESULTS
A total of 23 tumor samples from effusions with primary tumor of breast (5), lung (5), ovary (8) , and GI tract (5, including esophageal and pancreatic) were used to construct the CMA. The proportion of tumor cells in the original block and the subsequent cores on CMA were similar (ranging from 5% to 90%, Fig. 1 and Table 2 ). In the majority of cases, although tumor cells were found in all cases when counting all 3 cores, 1 or 2 cores did not have tumor cells in 4 cases that had a low tumor-cell burden (10%) in the original cell block (Fig. 1 , top left core with no cells). To determine the potential usefulness of using CMA for multiple marker testing, tumor cell composition at a deeper section of CMA (Section 45) was compared with the original section and the first section of CMA. At deeper Section 45, all cases except 1 (This case was exhausted by Section 30.) had at least 2 cores, and 19 cases still had all 3 cores present, all having a percentage of tumor cells similar to that of the original cell block sections (Table 2) . AE1/AE3 antibody stained all 23 cases (Fig. 1 , bottom 2 rows) on core biopsy (CB) (Fig. 2A 0 ) and CMA stained 21 strongly and 2 moderately ( Fig. 2A , and Table 3 ). EMA antibody stained 21 cases strongly or moderately (Table 3 , Fig. 2B and B 0 ) while the other 2 cases had only rare tumor cells on the core to compare with the original cell block section and thus were not included. Immunostains of AE1/AE3 and EMA were mostly strongly positive (rare cases moderately positive) in CMA and showed 100% concordance between the originals and their corresponding cores on CMA regarding intensity and high percentage of positive tumor cells (Table 3) . Ki-67 antibody stained 16 cases similarly between the original block section and CMA (11 cases strong, 3 cases moderate, and 2 cases weak; Fig. 2C and C 0 ), while 3 cases scored differently. Four cases with no tumor cells present or with rare tumor cells were not stained for scoring (Table 3) . Therefore, Ki-67 antibody showed somewhat lower concordance (84%, 16 of 19 cases). Excluded were the 4 cases where there was either low tumor burden because the tumor cells were less than 10% in original sections and there were no tumor cells in CMA, or because only rare tumor cells were present but not stained in CMA.
Similarly, although CK7, CK20, ER, PR, TTF-1, and WT-1 were only tested for selected cases, they stained both original sections (Fig. 2D-I ) and CMA ( Fig. 2D 0 -I 0 ) with a high level of agreement ( Table 4 ). The tumor cells stained from negative (less than 5% tumor cell stained) to positive (more than 5% and up to 100% tumor cells stained), and the overall staining pattern (cytoplasmic for CK7, CK20, or nuclear for ER, PR, TTF-1, and WT-1) and intensity of the original blocks were recapitulated by CMA cores.
DISCUSSION
TMA allows more rapid validation of multiple immunohistochemical markers than the conventional individual case-based method. 2 There have been reports using bone marrow biopsy material, fine-needle aspiration, and cell block material for array construction, 9-11 but multiple marker validation study using CMA from effusions has not been performed. 9 This study used 3 cores, each 0.6 mm in diameter, from effusion cell blocks of different primary tumors to construct a CMA. It showed that CMA was representative of the original cell blocks with tumor cell composition at deeper sections (to Section 45), and that immunostaining pattern, intensity, and percentage were similar to that of the original section for antibodies tested. Concordance was high, from 84% for Ki-67 to 100% for AE1/AE3 and EMA. There were rare cases where low tumor burden in the original block coupled with low percentage of staining by an antibody (mostly noticeable in Ki-67 staining) resulted in slightly lower concordance. In this study, CMA was constructed from cell blocks made by methods similar to surgical pathology specimens (fixation with 10% buffered formalin solution). However, for cytological specimens which have been processed differently (fixation by alcohol or methanol), additional testing is needed before accepting CMA as a routine marker testing tool because it is known that other fixations might not be optimal for detection of some markers, such as ER and PR. 12, 13 In the authors' experience, however, different thrombin clot cell block methods (fixation in 10% formalin) with or without specimens first being fixed in a methanol-based fixative such as CytoLyt (Cytyc Corporation, Malborough, Mass) have similar immunostain profiles in several markers tested, including ER and PR (C.W. Michael, unpublished data).
In this study, the 3 cores in CMA were representative of the original CB in the majority of cases. Only in rare instances did all 3 cores have no tumor cells or low tumor cells that were not stained for purpose of scoring. The necessity of using multiple cores in TMA has been demonstrated in reducing the nonconcordance rate. In one study, nonconcordance rate was 9.4% for single core, 4.4% for 2 cores, and 3.7% for 3 cores. 2 In some reports, single-core TMA has been shown to have rather satisfactory reliability (95%-98% concordance with whole tissue section) in detecting protein expression and gene amplification in breast cancer. 3, 14 Because cell blocks from effusions and other cytological samples tend to have smaller tissue fragments or cell clusters than a histological sample, a loss of 1 to 3 cores in rare cases and no tumor cells in 1 of the 3 cores in the deeper section in a few others was observed, arguing for using 3 cores in constructing a CMA to increase its representation of the original material.
In addition, although only 9 commonly used antibodies were tested, the estimated cost associated with constructing the CMA and staining 9 CMA slides is less than $1000, with the majority of the cost incurred in constructing CMA (from $400 to $800 depending on the type of array and institution), while the cost of staining with 9 antibodies is much less ($250; approximately $25 per stain 39). It translated into a saving of more than 50% when compared with the cost of testing all 9 antibodies on original cell block sections ($2500, $25 3ap-proximately 120 sections). Additional marker testing using this CMA would lead to more cost savings in research or clinical operations.
In conclusion, although a pilot study, it is demonstrated here for the first time that CMA is a reliable method for validating immunocytochemical markers in research or clinical laboratories. CMA can represent the original cell block material accurately in tumor cell composition and in testing of commonly used antibodies in staining of cytoplasm, membrane, and nuclei. Therefore, it could be easily deployed in either research or clinical laboratories for a rapid marker validation. Although the initial construction of CMA is neither simple nor inexpensive, the potential for high-volume testing makes it cost efficient despite the initial costs associated with a CMA construction. n/a n/a n/a n/a Positive -5 ---3 -2 n/a n/a n/a n/a Lung (5) Negative --5 -n/a n/a n/a n/a n/a n/a 1 -Positive -5 --n/a n/a n/a n/a n/a n/a -4 Ovary (8) Negative n/a n/a n/a n/a n/a n/a n/a n/a 1 -n/a n/a Positive n/a n/a n/a n/a n/a n/a n/a n/a -7 n/a n/a GI (5) Negative 1 1* 5 -n/a n/a n/a n/a n/a n/a n/a n/a Positive -3 --n/a n/a n/a n/a n/a n/a n/a n/a n/a indicates not stained for the antibody. *Indicates the low or no tumor cells to score on CMA.
